Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome

Erman, Hande; Beydogan, Engin; Cetin, Seher Irem; Böyük, Banu

doi:10.1155/2020/3534042

Cited by 13 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Janke et al suggested that insulin resistance could increase ESM-1 expression in adipocytes although circulating levels of Endocan were actually lower and no associations were found between circulating Endocan levels and ESM-1 gene expression in adipocytes. A recent study performed by Erman et al [ 23 ] also found similar results in the adult population. In this study, the authors found lower Endocan levels in adult NAFLD patients and suggested that Endocan levels could be a predictive biomarker for metabolic syndrome.…”

Section: Resultssupporting

confidence: 71%

Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Balanescu

Codreanu

Comanici

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

The aim of the study was to evaluate serum Endocan and Lumican levels as biomarkers for pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and to explore their associations with pediatric cardiometabolic risk factors. We conducted a cross-sectional study on 68 pediatric obese and overweight (O&O) patients. Ten healthy controls were recruited. Serum Lumican and Endocan levels were analyzed using ELISA kits. O&O patients had lower levels of Endocan compared to healthy controls (p<0.001). There were no differences between serum Endocan levels in O&O patients with NAFLD and those without (p=0.53). Patients considered having Nonalcoholic Steatohepatitis (NASH) had lower Endocan levels compared to O&O patients without NASH (p=0.026). Patients with metabolic syndrome had lower levels of Endocan (p=0.003). There were no significant differences between serum Lumican levels in O&O children compared to healthy controls. Lumican levels were higher in patients with hypertension (p=0.04). In O&O patients, Lumican levels were negatively correlated with Endocan levels (r=−0.37, p=0.002). Endocan seems a promising biomarker for the evaluation of pediatric NASH. Lumican was not confirmed as a biomarker for NAFLD in our cohort but was associated with higher arterial pressure. Low Endocan levels are accompanied by high serum Lumican levels, and this could be an early signature of cardiometabolic risk.

show abstract

Section: Resultssupporting

confidence: 71%

Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Balanescu

Codreanu

Comanici

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…ERP29, a chaperone protein, has been reported to be positively associated with BMI and to have a role in proinsulin secretion [39]. Of the replicated proteins, endothelial cell-specific molecule 1 (ESM1), has been reported to be low in liver steatosis in MetS patients [40] and in macroalbuminuria in T2D patients [41], both of which are in line with the negative association between ESM1 and MetS observed here. However, ESM1 was reported to be positively associated with atherosclerotic CVD [42].…”

Section: Mendelian Randomizationsupporting

confidence: 85%

Metabolic syndrome and the plasma proteome: from association to causation

Elhadad

Wilson

Zaghlool

et al. 2021

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background The metabolic syndrome (MetS), defined by the simultaneous clustering of cardio-metabolic risk factors, is a significant worldwide public health burden with an estimated 25% prevalence worldwide. The pathogenesis of MetS is not entirely clear and the use of molecular level data could help uncover common pathogenic pathways behind the observed clustering. Methods Using a highly multiplexed aptamer-based affinity proteomics platform, we examined associations between plasma proteins and prevalent and incident MetS in the KORA cohort (n = 998) and replicated our results for prevalent MetS in the HUNT3 study (n = 923). We applied logistic regression models adjusted for age, sex, smoking status, and physical activity. We used the bootstrap ranking algorithm of least absolute shrinkage and selection operator (LASSO) to select a predictive model from the incident MetS associated proteins and used area under the curve (AUC) to assess its performance. Finally, we investigated the causal effect of the replicated proteins on MetS using two-sample Mendelian randomization. Results Prevalent MetS was associated with 116 proteins, of which 53 replicated in HUNT. These included previously reported proteins like leptin, and new proteins like NTR domain-containing protein 2 and endoplasmic reticulum protein 29. Incident MetS was associated with 14 proteins in KORA, of which 13 overlap the prevalent MetS associated proteins with soluble advanced glycosylation end product-specific receptor (sRAGE) being unique to incident MetS. The LASSO selected an eight-protein predictive model with an (AUC = 0.75; 95% CI = 0.71–0.79) in KORA. Mendelian randomization suggested causal effects of three proteins on MetS, namely apolipoprotein E2 (APOE2) (Wald-Ratio = − 0.12, Wald-p = 3.63e−13), apolipoprotein B (APOB) (Wald-Ratio = − 0.09, Wald-p = 2.54e−04) and proto-oncogene tyrosine-protein kinase receptor (RET) (Wald-Ratio = 0.10, Wald-p = 5.40e−04). Conclusions Our findings offer new insights into the plasma proteome underlying MetS and identify new protein associations. We reveal possible casual effects of APOE2, APOB and RET on MetS. Our results highlight protein candidates that could potentially serve as targets for prevention and therapy.

show abstract

“…Also, Elsheikh et al, (2014) reported that endocan (as a marker for endothelial dysfunction) was also increased in NAFLD [10] . Also, NAFLD subjects had signi cantly higher endocan levels than control group as reported with Ustyol et al, (2017) [31] .…”

Section: Discussionsupporting

confidence: 68%

Novel Predictors Of Early Atherosclerosis In Non Alcoholic Fatty Liver Disease

Abdulaziz

Bendary

Thabet

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Non alcoholic fatty liver disease is regarded the most relevant liver disease of the twenty-first century, affecting at least one third of the general population. NAFLD is associated with increased mortality due to cardiovascular disease (CVD) and cancer. The carotid intimal media thickness (CIMT), mean platelet volume (MPV) and endocan level, could be markers for generalised atherosclerotic burden and endothelial dysfunction. Aims: To evaluate the association between non alcoholic fatty liver disease and early atherosclerosis by measuring CIMT, mean platelet volume (MPV) and endocan level, as markers of endothelial dysfunction, in NAFLD patients. Methods: This cross –sectional study included 50 patients who divided into two groups; group I included 25 subjects with NAFLD and group II included 25 healthy subjects. Complete blood count with mean platelet volume (MPV), Liver profile, Lipid profile, Fasting blood glucose level and 2 hour postprandial, Kidney function test, Serum concentrations of endocan were measured for all patients. NAFLD fibrosis score (NFS) was calculated. Abdominal ultrasonography and Carotid ultrasound scan for measurement of CIMT were performed. Results: Serum endocan levels, MPV and CIMT were significantly higher (p<0.005) in NAFLD patients (0.6, 9.3±1.2 and 0.9±0.3 respectivly) than healthy subjects (0.1, 8.1±0.6 and 0.6±0.1 respectively). The analysis of diagnostic performance of these factors revealed that they have good sensitivity and specificity in prediction of endothelial dysfunction with AUC (0.950, 0.844 and 0.849 respectivly). Conclusions:Serum endocan levels, MPV and CIMT could be considered as good predictors of endothelial dysfunction and therefore early detection of subclinical atherosclerosis in NAFLD patients.

show abstract

Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome

Cited by 13 publications

References 38 publications

Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Metabolic syndrome and the plasma proteome: from association to causation

Novel Predictors Of Early Atherosclerosis In Non Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About